Tenax Therapeutics, Inc. (TENX)
$
6.05
-0.10 (-1.65%)
Key metrics
Financial statements
Free cash flow per share
-0.4541
Market cap
25.5 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
40.4837
Income quality
0.6861
Average inventory
0
ROE
-0.3151
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products aimed at treating cardiovascular and pulmonary diseases in the United States and Canada. The company reported selling, general, and administrative expenses of $6,785,000.00 indicating its operational overhead costs. It is currently developing TNX-103 and TNX-102 (levosimendan), which have successfully completed phase II clinical trials targeting pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension. Additionally, TNX-201 (imatinib), a tyrosine kinase inhibitor, is being explored for treating pulmonary arterial hypertension. The net income ratio is 0.00 reflecting the company's profitability margin, while the income before tax ratio stands at 0.00 indicating its pre-tax margin. Furthermore, the net total of other income and expenses is $1,892,000.00 which illustrates the impact of non-core financial activities. The earnings per share (EPS) is reported at -$1.15 highlighting the company's profitability on a per-share basis. Tenax Therapeutics, previously known as Oxygen Biotherapeutics, Inc. until its name change in September 2014, has been making strides in the specialty pharmaceuticals field since its founding in 1967 and is headquartered in Morrisville, North Carolina. The stock is affordable at $6.15 making it an attractive option for budget-conscious investors. Despite its potential, the stock has a low average trading volume of 23,014.00 indicating lower market activity. With a market capitalization of $25,098,365.00 the company is classified as a small-cap player, positioning it as a key participant in the Biotechnology industry and contributing significantly to the overall market landscape. Its affiliation with the Healthcare sector underscores its role in driving innovation and growth within its field. As Tenax Therapeutics continues to expand its product pipeline, its strategic focus on addressing critical health issues in cardiovascular and pulmonary domains may enhance its position further in the competitive pharmaceutical landscape.
Is Tenax Therapeutics, Inc. (TENX) a good investment?
Investing in Tenax Therapeutics, Inc. (TENX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Tenax Therapeutics, Inc. (TENX)'s stock forecast?
Analysts predict Tenax Therapeutics, Inc. stock to fluctuate between $2.77 (low) and $7.89 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tenax Therapeutics, Inc.'s market capitalization?
As of 2025-05-30, Tenax Therapeutics, Inc.'s market cap is $25,098,365, based on 4,148,490 outstanding shares.
How does Tenax Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Tenax Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tenax Therapeutics, Inc. (TENX) stock?
To buy Tenax Therapeutics, Inc. (TENX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TENX. Place an order (Market, Limit, etc.).
What is the best time to invest in Tenax Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Tenax Therapeutics, Inc. stock ever split?
Tenax Therapeutics, Inc.'s last stock split was 1:80 on 2024-01-03.
How did Tenax Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.15 | Growth: -96.30%.
Where can I find Tenax Therapeutics, Inc.'s investor relations reports?
Visit https://www.tenaxthera.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tenax Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Tenax Therapeutics, Inc. stock?
All-time high: $4,864 (2021-02-10) | All-time low: $2.77 (2024-06-21).
What are the key trends affecting Tenax Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
17 days ago
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
seekingalpha.com
2 months ago
Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.
globenewswire.com
2 months ago
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.
globenewswire.com
2 months ago
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027
globenewswire.com
3 months ago
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses.
globenewswire.com
3 months ago
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025
globenewswire.com
3 months ago
CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL.
globenewswire.com
4 months ago
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY.
seekingalpha.com
7 months ago
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.
globenewswire.com
7 months ago
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors
See all news
